MedDay has developed a SPECMET research platform in partnership with Assistance Publique Hopitaux de Paris (APHP) and Commissariat à l’Energie Atomique (CEA) to support the discovery of additional pipeline assets. This platform identifies new therapeutic targets through cerebrospinal fluid metabolomic analysis. In March 2017, MedDay acquired all the health-related assets from Profilomic, an innovative company formed out of Commissariat à l’Energie Atomique (CEA) in 2010. The acquisition included its extensive database and laboratory equipment alongside its highly skilled scientists with world-class expertise in the field of metabolomics and lipidomics.

The SPECMET metabolomics platform screens cerebrospinal fluid (CSF) from patients with CNS disorders to identify metabolic pathways that are disrupted. The CSF is a medium of choice because of its proximity to neuronal and glial cells. The ultimate goal of this approach is to identify drugs able to target the aberrant pathways.

  • A biobank of 700 CSF samples corresponding to all major neurodegenerative diseases as well as rare inborn errors of metabolism has been constituted in collaboration with Assistance Publique Hôpitaux de Paris (APHP).
  • A  LC-MS based metabolomics approach has been set up to study approximately 2000 CSF small compounds per CSF sample, including different classes of lipids. This involves close collaboration with the Commissariat à l’Energie Atomique (CEA).
  • MedDay has invested in the platform and has exclusive rights for the exploitation of metabolomic signatures.

MedDay SA au capital de 116 660 €
Siège social : 96 Boulevard Haussmann 75008 Paris
RCS PARIS 534 957 865
Publication Director : Dr Frédéric Sedel